

US FDA clears Gambro BCT's software for interface with blood center information systems

(Local US press release)

Denver, CO, October 15, 2003 – Gambro BCT, Inc., a wholly owned subsidiary of Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it has received US Food and Drug Administration market clearance for the two-way software interface between the Vista™ Information System and Wyndgate Technologies®' SafeTrace® blood center software, to share critical donor, blood collection and blood center operations information.

“Vista is a cutting-edge software solution connecting donors, blood center operations and blood collection devices,” stated David Perez, President of Gambro BCT. Vista features component blood loss tracking, collection device interfaces, automated donor management, and business decision support. Mr. Perez added, “We designed Vista with customer application connectivity in mind. We are very happy to realize Vista's potential in our alliance with Wyndgate and make this valuable integration available to SafeTrace customers.”

Technical trials for the two-way Vista and SafeTrace interface were conducted at the San Diego Blood Bank in California. The San Diego Blood Bank is an independent blood center serving approximately 50 hospitals in the Southern California Region. “The connectivity between Vista and SafeTrace reduces errors, eliminates duplicate data entries, streamlines donor record management, and contributes to our goal of ‘paperless’ processing,” commented Ramona Walker, Chief Executive Officer of the San Diego Blood Bank. Ms. Walker added, “With Gambro BCT's Trima Accel Automated Blood Collection System, Vista and SafeTrace, we now have state of the art technology that benefits our community, our donors and ultimately the patients who need blood transfusions.”

“The integration of Trima and SafeTrace enables blood centers to share critical donor information easily, in real time, creating a powerful automated management system for blood centers,” said Thomas F. Marcinek, President and COO of Wyndgate Systems. Mr. Marcinek added, “Our SafeTrace customers will benefit from increased productivity, reduced paperwork, higher quality products, and improved donor care and safety.”

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 54,770 patients in more than 700 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2002 revenues of approximately SEK 27.6 billion (USD 2.7 billion), has 21,300 employees in some 40 countries.

Gambro BCT, Inc.
10811 Collins Avenue
Lakewood, CO 80215
USA
Tel 303 232 6800
Fax 303 231 4150
www.gambrobct.com

About Wyndgate Technologies

Wyndgate Technologies, a division of Global Med Technologies, Inc. is a leading supplier of information management systems to US blood centers, hospital blood banks and transfusion services. Current clients of Wyndgate's products and services manage more than 3 million units of blood or over 22% of the US blood supply each year.

About Gambro BCT

Gambro BCT, headquartered in Lakewood, Colorado, is a world leader in blood bank technologies, automated blood collection, pathogen reduction techniques, and value added blood and cell based therapeutic services.

For further information please contact:

David Perez, President, Gambro BCT, tel. +1-303-232-6800

Ellen Cohig, Marketing Communications Manager, Gambro BCT, tel. +1-303-231-4145

or visit the website www.gambrobct.com

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 54,770 patients in more than 700 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2002 revenues of approximately SEK 27.6 billion (USD 2.7 billion), has 21,300 employees in some 40 countries.

Gambro BCT, Inc.
10811 Collins Avenue
Lakewood, CO 80215
USA
Tel 303 232 6800
Fax 303 231 4150
www.gambrobct.com